Core Viewpoint - 永泰生物-B (06978) has proposed a rights issue at a subscription price of HKD 2.5 per share, aiming to raise up to HKD 2.57 billion or HKD 3.08 billion depending on the conversion of convertible bonds and exercise of options [1] Group 1: Rights Issue Details - The company plans to issue up to 103 million shares, or 123 million shares if all convertible bonds are converted and options exercised, based on a record date of existing shares [1] - The rights issue is structured such that for every 5 existing shares held, shareholders will receive 1 new share [1] Group 2: Use of Proceeds - Approximately 54% of the net proceeds from the rights issue will be allocated for EAL clinical trials [1] - About 24% will be used to expand research and development expenses for other clinical indications of EAL [1] - The remaining 22% will be directed towards general operating funds of the group [1] Group 3: Trading Resumption - The company has applied to the Hong Kong Stock Exchange for the resumption of trading of its shares starting from September 22, 2025, at 9:00 AM [1]
永泰生物-B拟按“5供1”基准进行供股 9月22日复牌